CSF2 and neuroblastoma: A phase Ib/II trial is testing another anti-GD2 mAb, naxitamab (approved for use in combination with GM-CSF for neuroblastoma in the bone or bone marrow) in combination with TGFβi NK cells and gemcitabine-based chemotherapy for the treatment of HER2-negative, GD2-positive metastatic breast cancer (NCT06026657) (130).